RAS

Events

Partner Content

For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible.

News

Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.